Search Results

Biotech Beach

Hillhurst Biopharmaceuticals Receives NIH Heal Initiative Award for Development of HBI-201 in Pain

Hillhurst Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing liquid drug products containing therapeutic gases, announced the award of an up to $5 million HEAL Initiative grant from the National Institutes of Health.

November 7, 2023

·

2 min read

Biotech Beach

Hillhurst Biopharma Completes Seed Financing to Advance Clinical Development

Hillhurst Biopharmaceuticals, Inc. announced the completion of a financing that, together with non-dilutive sources, funds Phase 2a clinical studies in sickle cell disease and in a second clinical indication.

December 20, 2023

·

2 min read

Drug Development

HILLHURST BIOPHARMACEUTICALS RECEIVES $3 MILLION IN NIH SBIR FUNDING FOR PHASE 2A CLINICAL STUDY IN SICKLE CELL DISEASE

Hillhurst Biopharmaceuticals, Inc. today announced the award of an approximately $3 million Phase 2b SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

September 20, 2023

·

2 min read

Drug Development

HILLHURST BIOPHARMACEUTICALS ANNOUNCES COMPLETION OF LAST PATIENT LAST VISIT IN PHASE 1 CLINICAL TRIAL OF HBI-002

Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”) today announced that the last participant has completed the study protocol of its U.S. Phase 1 clinical trial of HBI-002, an oral low dose carbon monoxide (CO) therapeutic candidate.

May 23, 2023

·

2 min read

Press Releases

Biopharmaceuticals Market Size Expected to Reach USD 1,796.21 Bn by 2034

February 17, 2025

·

1 min read

Press Releases

U.S. Biopharmaceuticals Market Size to Surpass USD 635.37 Billion by 2034

February 19, 2025

·